This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Brodsky, D. Articles by Christou, H. Search for Related Content PubMed PubMed Citation Articles by Brodsky, D. Articles by Christou, H. Pubmed/NCBI databases Medline Plus Health Information High Risk Pregnancy Social Bookmarking                   What's this?

Current Concepts in Intrauterine Growth Restriction

Beth Israel Deaconess Medical Center, Department of Newborn Medicine, Rose 3, 330 Brookline Avenue, Boston, MA 02215dbrodsky{at}bidmc.harvard.edu

Helen Christou, MD

Regulation of fetal growth is multifactorial and complex. Diverse factors, including intrinsic fetal conditions as well as maternal and environmental factors, can lead to intrauterine growth restriction (IUGR). The interaction of these factors governs the partitioning of nutrients and rate of fetal cellular proliferation and maturation. Although IUGR is probably a physiologic adaptive response to various stimuli, it is associated with distinct short- and long-term morbidities. Immediate morbidities include those associated with prematurity and inadequate nutrient reserve, while childhood morbidities relate to impaired maturation and disrupted organ development. Potential long-term effects of IUGR are debated and explained by the fetal programming hypothesis. In formulating a comprehensive approach to the management and follow-up of the growth-restricted fetus and infant, physicians should take into consideration the etiology, timing, and severity of IUGR. In addition, they should be cognizant of the immediate perinatal response of the growth-restricted infant as well as the childhood and long-term associated morbidities. A multi disciplinary approach is imperative, including early recognition and obstetrical management of IUGR, assessment of the growth-restricted newborn in the delivery room, possible monitoring in the neonatal intensive care unit, and appropriate pediatric follow-up. Future research is necessary to establish effective preventive, diagnostic, and therapeutic strategies for IUGR, perhaps affecting the health of future generations.

Key Words: intrauterine growth restriction • small for gestational age

Journal of Intensive Care Medicine, Vol. 19, No. 6, 307-319 (2004)
DOI: 10.1177/0885066604269663


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. Roos, Y. Kanai, P. D. Prasad, T. L. Powell, and T. Jansson Regulation of placental amino acid transporter activity by mammalian target of rapamycin Am J Physiol Cell Physiol, January 1, 2009; 296(1): C142 - C150. [Abstract] [Full Text] [PDF]

				V. Jakoubek, J. Bibova, J. Herget, and V. Hampl Chronic hypoxia increases fetoplacental vascular resistance and vasoconstrictor reactivity in the rat Am J Physiol Heart Circ Physiol, April 1, 2008; 294(4): H1638 - H1644. [Abstract] [Full Text] [PDF]

				D. A. Evseenko, P. Murthi, J. W. Paxton, G. Reid, B. S. Emerald, K. M. Mohankumar, P. E. Lobie, S. P. Brennecke, B. Kalionis, and J. A. Keelan The ABC transporter BCRP/ABCG2 is a placental survival factor, and its expression is reduced in idiopathic human fetal growth restriction FASEB J, November 1, 2007; 21(13): 3592 - 3605. [Abstract] [Full Text] [PDF]

				R. J. Edison, K. Berg, A. Remaley, R. Kelley, C. Rotimi, R. E. Stevenson, and M. Muenke Adverse Birth Outcome Among Mothers With Low Serum Cholesterol Pediatrics, October 1, 2007; 120(4): 723 - 733. [Abstract] [Full Text] [PDF]

				S. Roos, N. Jansson, I. Palmberg, K. Saljo, T. L. Powell, and T. Jansson Mammalian target of rapamycin in the human placenta regulates leucine transport and is down-regulated in restricted fetal growth J. Physiol., July 1, 2007; 582(1): 449 - 459. [Abstract] [Full Text] [PDF]

				A. Malamitsi-Puchner, D. D. Briana, L. Kontara, M. Boutsikou, S. Baka, D. Hassiakos, A. Marmarinos, and D. Gourgiotis Serum Cystatin C in Pregnancies With Normal and Restricted Fetal Growth Reproductive Sciences, January 1, 2007; 14(1): 37 - 42. [Abstract] [PDF]

				R. Geva, R. Eshel, Y. Leitner, A. F. Valevski, and S. Harel Neuropsychological Outcome of Children With Intrauterine Growth Restriction: A 9-Year Prospective Study Pediatrics, July 1, 2006; 118(1): 91 - 100. [Abstract] [Full Text] [PDF]

				D. G. Oelberg Consultation with the Specialist: Prenatal Growth: The Sum of Maternal, Placental, and Fetal Contributions Pediatr. Rev., June 1, 2006; 27(6): 224 - 229. [Full Text] [PDF]

				P. Murthi, V. L. Doherty, J. M. Said, S. Donath, S. P. Brennecke, and B. Kalionis Homeobox gene ESX1L expression is decreased in human pre-term idiopathic fetal growth restriction Mol. Hum. Reprod., May 1, 2006; 12(5): 335 - 340. [Abstract] [Full Text] [PDF]

				K. Yang, L. Julan, F. Rubio, A. Sharma, and H. Guan Cadmium reduces 11{beta}-hydroxysteroid dehydrogenase type 2 activity and expression in human placental trophoblast cells Am J Physiol Endocrinol Metab, January 1, 2006; 290(1): E135 - E142. [Abstract] [Full Text] [PDF]